Table 5.
Development in quality of life during 64 days of BP-C1 treatment and 28 days of follow-up
| Variable | Screening (n=19) |
Day 16 (n=19) |
Day 32 (n=19) |
Day 48 (n=18) |
Day 64 (n=18) |
Final (n=19) |
P-value |
|---|---|---|---|---|---|---|---|
| Physical activity problems | 7.9 | 7.3 | 7.2 | 7.1 | 7.0 | 7.3 | 0.02 |
| 7.1–8.8 | 6.5–8.1 | 6.4–8.4 | 6.2–8.0 | 6.3–7.8 | 6.4–8.2 | 0.05 | |
| Discomfort last week | 33.7 | 32.8 | 32.7 | 32.6 | 32.2 | 33.7 | 0.08 |
| 30.2–37.2 | 29.7–35.9 | 29.4–36.0 | 29.1–36.1 | 28.8–35.6 | 29.6–37.8 | 0.23 | |
| Health and life quality | 9.1 | 8.8 | 8.9 | 9.5 | 9.2 | 8.4 | 0.50 |
| 7.9–10.2 | 7.8–9.8 | 7.9–9.9 | 8.3–10.7 | 8.0–10.3 | 7.0–9.9 | 0.07 | |
| BC treatment problems last week | 20.8 | 20.1 | 20.1 | 19.4 | 19.6 | 20.1 | 0.05 |
| 18.8–22.9 | 18.1–22.0 | 17.8–22.3 | 17.2–21.7 | 17.5–21.6 | 17.8–22.4 | 0.39 | |
| Sexual interest and activity, last 4 weeks | 2.9 | 3.1 | 3.0 | 2.7 | 2.8 | 2.8 | 0.13 |
| 2.2–3.7 | 2.4–3.9 | 2.4–3.6 | 2.1–3.4 | 2.0–3.5 | 2.1–3.6 | 0.35 | |
| BC-related pain and discomfort last week | 11.7 | 11.4 | 11.1 | 10.9 | 10.7 | 11.7 | 0.03 |
| 9.6–13.8 | 9.4–13.4 | 9.3–12.8 | 8.6–13.2 | 8.7–12.7 | 9.6–13.9 | 0.47 |
Notes: Results are expressed as mean and 95% confidence intervals. The upper P-values refer to changes from screening to Day 64 and the lower to changes from screening to final examination 28 days after the last injection.
Abbreviations: BC, breast cancer; BP-C1, benzene-poly-carboxylic acids complex with cis-diammineplatium (II) dichloride.